List of Excipients in Branded Drug CARNITOR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Leadiant Biosciences Inc	CARNITOR	levocarnitine	54482-144	CELLULOSE, MICROCRYSTALLINE
Leadiant Biosciences Inc	CARNITOR	levocarnitine	54482-144	MAGNESIUM STEARATE
Leadiant Biosciences Inc	CARNITOR	levocarnitine	54482-144	POVIDONE
Leadiant Biosciences Inc	CARNITOR	levocarnitine	54482-145	MALIC ACID
Leadiant Biosciences Inc	CARNITOR	levocarnitine	54482-145	METHYLPARABEN
Leadiant Biosciences Inc	CARNITOR	levocarnitine	54482-145	PROPYLPARABEN

Carnitor Excipient Strategy and Commercial Opportunities for Levocarnitine

Last updated: August 16, 2026

Carnitor is a mature levocarnitine product with limited composition-of-matter protection and established generic competition. The strongest commercial opportunities are excipient-led: improved palatability, preservative-free pediatric delivery, higher-concentration oral liquids, ready-to-use injectable presentations, and differentiated products for patients with renal, metabolic, or swallowing limitations. Patent value is more likely to arise from formulation, container-closure, manufacturing, or method-of-use claims than from levocarnitine itself.

What is Carnitor and which levocarnitine formulations are marketed?

Carnitor contains levocarnitine, the biologically active L-isomer of carnitine. FDA-approved Carnitor presentations include oral tablets, oral solution, and injection. The products are indicated for the treatment of primary and secondary carnitine deficiency. [1]

Product	Strength	Dosage form	Primary commercial use
Carnitor tablets	330 mg	Immediate-release tablet	Chronic outpatient therapy
Carnitor oral solution	1 g/10 mL	Oral liquid	Pediatric, geriatric, and swallowing-limited patients
Carnitor injection	200 mg/mL	Injectable solution	Intravenous use and acute or supervised treatment

Levocarnitine is also available from multiple generic manufacturers in tablets, oral solution, and injectable products. Generic competition limits the ability to defend price through the active ingredient alone. [2]

What excipients are relevant to Carnitor?

The commercial relevance of Carnitor excipients differs by dosage form.

Dosage form	Excipient priorities	Key development risks
Tablet	Compression, disintegration, moisture control, swallowability	Dose size, tablet burden, friability
Oral solution	Taste masking, microbial protection, pH control, viscosity, palatability	High daily dose, preservative exposure, chemical stability
Injection	Tonicity, pH, particulate control, container compatibility, sterility	Intravenous tolerability, degradation, extractables and leachables
Powder or granule	Reconstitution, taste, moisture protection, dose accuracy	Uniformity and patient handling
Unit-dose liquid	Packaging, stability, portability, dosing accuracy	Container compatibility and cost of goods

Carnitor oral products carry a particular excipient challenge because levocarnitine is typically administered in gram-level daily doses. A formulation that improves taste but increases viscosity, volume, or sugar content may reduce adherence or create new regulatory concerns.

What excipient strategy best protects a new levocarnitine product?

The strongest strategy is to select a defined patient segment and link the excipient system to a measurable clinical or usability benefit.

Pediatric taste-masked oral solution

The most direct opportunity is a pediatric oral liquid with improved taste and reduced administration burden. Levocarnitine solutions can have a strong, distinctive taste that affects adherence. A differentiated product could use:

• Flavor systems compatible with acidic aqueous formulations.
• High-intensity sweeteners or low-sugar systems.
• Ion-exchange resins or cyclodextrin-based taste masking.
• Microencapsulated levocarnitine particles.
• Lower-volume, higher-concentration dosing.
• Unit-dose oral syringes with dose markings.

Taste masking must be evaluated against dose loading. A resin complex or coating system that works at low active-drug levels may become impractical when the daily dose is several grams.

A commercially attractive design would combine a higher concentration with a dosing device that limits administration volume. The product would need comparative stability, dose-uniformity, redispersibility if suspended, and palatability data.

Sugar-free and low-sodium formulations

Patients with metabolic disorders, renal disease, diabetes, or chronic treatment needs may benefit from sugar-free formulations. Sodium content is also relevant when the formulation uses sodium-containing buffers, sweeteners, or preservatives.

Potential positioning includes:

• Sugar-free oral solution.
• Low-sodium oral solution.
• Preservative-free unit-dose product.
• Alcohol-free and dye-free pediatric product.
• Formulation compatible with enteral feeding tubes.

A sugar-free formulation has a clearer commercial rationale than a cosmetic flavor change because it can address dietary restrictions and institutional formulary preferences.

Preservative-free multidose or unit-dose liquids

Preservatives can create tolerability and labeling issues, particularly in pediatric and chronic-use populations. A preservative-free product could use:

• Unit-dose ampoules.
• Blow-fill-seal packaging.
• A sterile or aseptically filled liquid.
• An antimicrobial container-closure system, where legally and technically appropriate.
• A reconstituted powder with a defined in-use period.

The tradeoff is higher packaging and manufacturing cost. A unit-dose system may be commercially viable where adherence, home administration, or hospital handling justifies the premium.

Tablet and mini-tablet strategies

Carnitor tablets are exposed to dose-burden limitations. Commercial alternatives include:

• Smaller-strength tablets for flexible titration.
• Scored tablets.
• Multiparticulate sachets.
• Sprinkle formulations.
• Orally disintegrating tablets.
• Mini-tablets for pediatric use.

An orally disintegrating tablet must address the large amount of levocarnitine required per dose. Direct compression may be difficult if the active ingredient has poor compactability or causes an unacceptable mouthfeel. Multiparticulate technology may provide better flexibility but increases manufacturing complexity.

Injectable formulation optimization

The injectable product creates a separate opportunity. Excipients should be minimized because intravenous administration increases the consequences of pH excursions, particulate contamination, osmolality changes, and container interaction.

Potential improvements include:

• Ready-to-use premixed bags or syringes.
• Preservative-free single-dose presentations.
• Improved low-temperature stability.
• Reduced overfill.
• Compatibility with common infusion solutions and administration sets.
• Container systems with lower extractables and leachables.
• Terminally sterilizable packaging, if feasible.

Ready-to-use presentations can reduce pharmacy preparation time and medication-error risk. The economic case is strongest in hospitals and dialysis settings, where labor, waste, and preparation controls affect product selection.

What patents protect Carnitor and levocarnitine formulations?

Levocarnitine is an established active pharmaceutical ingredient, and the principal commercial protection opportunity is not a new chemical entity patent. Relevant protection would generally fall into five categories:

1. Formulation composition claims.
2. Taste-masking or particle-engineering claims.
3. Container-closure and delivery-device claims.
4. Manufacturing and sterilization claims.
5. Method-of-use claims for defined patient populations or dosing regimens.

What is the Orange Book status of Carnitor?

FDA’s Orange Book identifies approved drug products and, where applicable, associated patents and regulatory exclusivity. Carnitor’s active ingredient is levocarnitine, and generic levocarnitine products have been approved in the same major dosage forms. [2]

For a new entrant, the relevant due-diligence questions are:

Issue	Commercial impact
Listed Carnitor patents	Determines potential Paragraph IV exposure
Approved generic products	Establishes substitution and pricing pressure
Therapeutic-equivalence ratings	Affects pharmacy substitution
Regulatory exclusivity	Can delay approval of certain competitors
Formulation differences	May require 505(b)(2) rather than 505(j)
Device or packaging claims	May support separate patent enforcement

No biosimilar pathway applies because levocarnitine is a small-molecule drug, not a biologic. The competitive pathway is generic approval under ANDA or, for a materially different formulation, a 505(b)(2) application. [3,4]

How strong is the patent estate for a new Carnitor formulation?

A new levocarnitine product could have a moderate formulation patent position if it claims a narrow, reproducible technical solution. The strongest claims would specify:

• A defined excipient concentration range.
• A particular pH and buffer system.
• Particle size or coating characteristics.
• A taste-masking mechanism.
• A stability profile under defined storage conditions.
• A device and formulation combination.
• A container-closure configuration that limits degradation or contamination.

Weak claims would cover routine excipients at broad concentrations without a demonstrated technical effect. Because many standard pharmaceutical excipients are well known, patentability depends on unexpected performance, improved stability, better palatability, lower dosing volume, or another measurable advantage.

A formulation patent does not automatically prevent all generic competition. A generic applicant may certify that the patent is not infringed, is invalid, or is not relevant to the proposed product. The scope of the claims and the product’s labeling determine practical enforcement risk.

When does Carnitor lose exclusivity?

Carnitor’s active ingredient is mature, and generic levocarnitine products are already marketed. The core commercial question is therefore not the future loss of basic exclusivity. It is whether a differentiated presentation can obtain market protection through patents, regulatory exclusivity, or product-level switching costs.

Protection type	Relevance to Carnitor
Composition-of-matter patent	Generally no meaningful remaining opportunity for levocarnitine
New formulation patent	Potentially relevant
Method-of-use patent	Potentially relevant but dependent on enforceable labeling and clinical evidence
Orphan-drug exclusivity	Could apply only to a qualifying new indication and approved product
New chemical entity exclusivity	Not available for established levocarnitine
505(b)(2) exclusivity	Potentially available in limited circumstances
Generic approval	Already established for major dosage forms

Orphan-drug exclusivity is indication-specific and does not create broad protection for all levocarnitine products. A sponsor would need an eligible disease or patient population and an FDA-approved orphan indication. [5]

Which companies are challenging Carnitor commercially?

The competitive field consists mainly of generic pharmaceutical manufacturers and specialty-drug companies supplying levocarnitine products. Generic competition is most relevant in:

• 330 mg tablets.
• 1 g/10 mL oral solutions.
• 200 mg/mL injections.
• Hospital and dialysis channels.
• Pharmacy-benefit formulary purchasing.

The competitive advantage of an excipient-differentiated product would depend on whether payers and pharmacies treat it as substitutable with existing products. An AB-rated generic may face lower reimbursement barriers than a branded 505(b)(2) formulation. A product with a distinct dosage form, delivery device, or labeling may avoid direct substitution but must earn a premium through clinical or operational value.

What generic entry risks exist for a new Carnitor formulation?

Generic entry risk is high for conventional formulations and lower for technically differentiated products.

High-risk commercial profiles

• Standard immediate-release tablets.
• Conventional oral solutions using common excipients.
• Injectable products with no container or administration advantage.
• Products relying only on a new flavor.
• Formulations with no meaningful labeling distinction.

Lower-risk profiles

• Low-volume, high-concentration pediatric liquids.
• Preservative-free unit-dose products.
• Products with validated tube-feeding compatibility.
• Ready-to-use injectable bags or syringes.
• Novel multiparticulate or taste-masked systems.
• Products protected by device, formulation, and manufacturing patents.

Even a technically superior product may face price pressure if the FDA considers it pharmaceutically equivalent to an existing generic. The sponsor should align formulation design with a regulatory pathway that preserves differentiation.

Should a new levocarnitine product use an ANDA or 505(b)(2) pathway?

An ANDA is appropriate when the proposed product can match the reference product in active ingredient, dosage form, strength, route, performance, and labeling, subject to applicable FDA requirements. It generally provides the lowest development cost but also the least commercial differentiation.

A 505(b)(2) application may be appropriate when the product changes the dosage form, delivery system, excipient platform, concentration, or clinical use in a way that requires reliance on existing FDA findings plus new supporting data. [3]

Development objective	Likely pathway
Standard tablet equivalent	ANDA
Standard oral solution equivalent	ANDA
New high-concentration liquid	ANDA or 505(b)(2), depending on equivalence
Taste-masked multiparticulate product	Often 505(b)(2)
New ready-to-use injectable presentation	ANDA or 505(b)(2), depending on formulation and packaging
New indication or dosing regimen	505(b)(2) or supplemental application
Novel excipient with limited prior FDA use	Higher regulatory burden under either pathway

The 505(b)(2) route can support differentiation but adds clinical, CMC, and regulatory costs. A sponsor should not select a novel excipient merely to create patent space. The excipient must provide a defensible benefit and have a manageable safety and regulatory profile.

What manufacturing and intellectual-property barriers affect levocarnitine excipient products?

Manufacturing barriers may create stronger practical protection than patents in some segments.

Important barriers include:

• Achieving acceptable taste at high drug loading.
• Preventing precipitation during storage.
• Maintaining assay and impurity limits across the shelf life.
• Controlling microbial growth in aqueous products.
• Producing sterile injectable units at commercial scale.
• Managing oxygen, light, and temperature sensitivity.
• Demonstrating compatibility with dosing syringes and feeding tubes.
• Controlling extractables and leachables in flexible packaging.
• Maintaining powder flow and content uniformity.
• Scaling coating or microencapsulation processes.

A robust intellectual-property package should combine composition claims with process and device claims. Trade-secret protection may be useful for flavor combinations, coating parameters, process controls, and scale-up methods, although it does not prevent independent development.

How large is the commercial opportunity for excipient innovation?

Levocarnitine is unlikely to support a broad premium strategy based solely on a new excipient. The opportunity is narrower and segment-driven.

Segment	Opportunity	Pricing potential
Pediatric metabolic patients	Taste masking, lower volume, dosing devices	Moderate to high
Chronic oral users	Sugar-free, preservative-free, adherence features	Moderate
Dialysis and renal-care settings	Injectable convenience and compatibility	Moderate
Hospitals	Ready-to-use injection and reduced preparation	Moderate to high
General generic market	Standard tablets and liquids	Low
Specialty pharmacy	Unit-dose, patient-specific packaging	Moderate

Revenue exposure for incumbent levocarnitine products is difficult to isolate because company disclosures often combine products within broader specialty or rare-disease portfolios. The most defensible commercial model is based on prescription volume, channel mix, net price, and conversion from existing generic products rather than on the branded product’s historical sales alone.

What licensing opportunities exist for Carnitor excipient technology?

Licensing opportunities are most credible in four areas:

1. Taste-masking platforms with prior human-use data.
2. High-drug-load liquid or multiparticulate technologies.
3. Ready-to-use sterile injectable packaging.
4. Pediatric dosing devices linked to a stable formulation.

A deal structure could include an upfront payment, development milestones, regulatory milestones, and royalties on net sales. The licensor should preserve rights to the technology outside levocarnitine if the platform has broader application.

Due diligence should cover:

• Ownership of formulation and process patents.
• Freedom to operate in the United States, Europe, and Japan.
• FDA precedent for the excipients.
• Stability and palatability data.
• Manufacturing scale-up history.
• Exclusivity of flavor, coating, or packaging suppliers.
• Patent term and continuation applications.
• Existing licenses to competing drug products.

Key Takeaways

• Carnitor is a mature levocarnitine product with generic competition in tablets, oral solution, and injection.
• The main commercial opportunity is excipient-led differentiation, not active-ingredient exclusivity.
• Pediatric taste masking, low-volume liquids, preservative-free products, and ready-to-use injections have the clearest value propositions.
• Conventional formulations have high generic entry risk and limited pricing power.
• Formulation, manufacturing, packaging, and device patents can create protection, but broad claims based on routine excipients are vulnerable.
• An ANDA offers lower cost but limited differentiation. A 505(b)(2) pathway may be justified for a materially different delivery system or clinical use.
• No biosimilar pathway applies to levocarnitine.
• The most defensible investment thesis combines a patient-specific benefit, validated excipient performance, a scalable manufacturing process, and layered intellectual-property protection.

FAQs

Can a sugar-free levocarnitine product obtain separate market protection?

A sugar-free product may obtain patent protection if the formulation provides a non-obvious technical benefit, such as improved stability, palatability, or preservative performance. Sugar-free status alone usually does not create meaningful exclusivity.

Is a taste-masked Carnitor product eligible for orphan-drug exclusivity?

Taste masking alone does not qualify a product for orphan-drug exclusivity. The product would need an eligible rare-disease indication and FDA orphan-drug designation followed by approval for that indication.

Can a levocarnitine oral solution be reformulated with a novel excipient?

Yes, but the regulatory burden increases if the excipient lacks adequate prior FDA use or safety support. The sponsor would need to address toxicology, exposure, manufacturing control, and product-specific safety.

Are levocarnitine formulations subject to Paragraph IV challenges?

A generic applicant can submit a Paragraph IV certification against relevant listed patents. The practical risk depends on whether the reference product has active Orange Book-listed patents covering the formulation, use, or delivery system.

Does a ready-to-use levocarnitine injection justify a premium price?

It can, particularly in hospitals or dialysis settings where reduced pharmacy preparation, lower waste, and lower medication-error risk produce measurable savings. The premium must exceed the added cost of sterile filling, packaging, and distribution.

References

1. U.S. Food and Drug Administration. (2023). Carnitor (levocarnitine) prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2).
4. U.S. Food and Drug Administration. (2020). ANDA submissions: Content and format.
5. U.S. Food and Drug Administration. (2023). Orphan drug designation and exclusivity.